Opthea's Wet AMD Trial Meets Primary Endpoint
Ticker: OPTEY · Form: 6-K · Filed: Mar 24, 2025 · CIK: 1815620
Sentiment: bullish
Topics: clinical-trial-results, biotech, ophthalmology
TL;DR
Opthea's sozinibercept hits primary endpoint in wet AMD Phase 3 trial, beating aflibercept on vision gain.
AI Summary
Opthea Ltd announced topline results for its Phase 3 COAST trial of sozinibercept for wet age-related macular degeneration (AMD) on March 24, 2025. The trial met its primary endpoint, demonstrating a statistically significant improvement in best corrected visual acuity (BCVA) compared to aflibercept. Full results will be presented at an upcoming medical congress.
Why It Matters
Positive results from the COAST trial could lead to regulatory approval for sozinibercept, offering a new treatment option for patients with wet AMD.
Risk Assessment
Risk Level: medium — While the trial met its primary endpoint, further regulatory review and market adoption will determine the ultimate success of sozinibercept.
Key Players & Entities
- Opthea Ltd (company) — Registrant
- sozinibercept (drug) — Investigational drug for wet AMD
- COAST (trial) — Phase 3 trial for sozinibercept
- aflibercept (drug) — Comparator drug in COAST trial
- March 24, 2025 (date) — Date of announcement
FAQ
What was the primary endpoint of the COAST Phase 3 trial?
The primary endpoint was the change from baseline in best corrected visual acuity (BCVA) at 52 weeks.
What was the comparator treatment in the COAST trial?
The comparator treatment was aflibercept.
What condition is sozinibercept being investigated for?
Sozinibercept is being investigated for the treatment of wet age-related macular degeneration (AMD).
When were the topline results announced?
The topline results were announced on March 24, 2025.
Where will the full results of the COAST trial be presented?
Full results will be presented at an upcoming medical congress.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 24, 2025 regarding Opthea Ltd (OPTEY).